Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Finranks

Компания

  • О нас

Контакты

  • [email protected]

Мы в соцсетях

  • Instagram
  • Telegram
  • LinkedIn

Все права защищены.

Условия использования
  • Главная
  • Рынки
  • Скринер
  • Новости
  • О нас
  1. Home
  3. LH
L

Labcorp Holdings Inc. (LH)

NYQ – Цена в реальном времени. Валюта: USD

264.20

-4.18 (-1.56%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

264.73

+0.53 (0.20%)

После закрытия: Mar 27, 2026, 6:19 PM EDT

  • Обзор
  • Новости
  • График
  • Финансы
  • Дивиденды
  • Прогноз
  • Владельцы
  • Профиль

Видео

No Data

There is no data to display

Пресс-релизы

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing
18.03.2026

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide
23.02.2026

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient care BURLINGTON, N.C., Feb. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations.

Labcorp Announces 2025 Fourth Quarter and Full Year Results
17.02.2026

Labcorp Announces 2025 Fourth Quarter and Full Year Results

Company Provides 2026 Guidance Financial results from Operations versus 2024: Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billion Diluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84 Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57 Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billion Provided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4% Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9% Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8% Expanded partnerships with health systems and regional/local laboratories by signing or closing 13 transactions in 2025 Advanced leadership in specialty testing, launching more than 130 innovative new tests in 2025, including in oncology, women's health, neurology and autoimmune Announced strategic investment to build a modern, state-of-the-art 500,000 square foot Central Laboratory facility to address growth in demand BURLINGTON, N.C.

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care
11.02.2026

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

Elecsys ® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology Now available nationwide in primary care settings for patients aged 55 and older experiencing symptoms of cognitive decline Expands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests across both primary and specialty care settings BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment of Alzheimer's disease in the primary care setting.